Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.
about
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationVaccines for Epidemic Infections and the Role of CEPIHendra virus and Nipah virus animal vaccines.Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus.Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine.Prediction of epitope-based peptides for the utility of vaccine development from fusion and glycoprotein of nipah virus using in silico approach.Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease.Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.Henipavirus Encephalitis: Recent Developments and Advances.Contribution of Human Lung Parenchyma and Leukocyte Influx to Oxidative Stress and Immune System-Mediated Pathology following Nipah Virus Infection.Efficacy of recombinant measles virus expressing highly pathogenic avian influenza virus (HPAIV) antigen against HPAIV infection in monkeys.
P2860
Q26700080-0160278D-EA3E-4BE1-90E7-B4CB851B0A3CQ29224804-60D3B7B6-4D0B-4FC2-88D3-22C8A409139CQ30387821-35779CAC-6AAA-4D29-8FCE-60393AAD0FB2Q33579992-1E4F96C2-0A75-496B-9F93-90A1C9280DC1Q33894405-8F8725AE-9221-492D-8263-D9DA66856B32Q34039928-330B9B20-DB51-49C3-92B6-88A1FE77EB38Q35613127-A9E2D143-CEDA-409B-B419-B73539A30AC4Q36791009-0302524A-9270-41CB-A6EF-6BF40AAD66C5Q37418736-65CAD517-8456-4AB4-B77F-F872F2A0EBDAQ38567114-C1020203-1D8E-43A2-85C4-83699C250F21Q38766458-4C34739E-E1B0-4CA5-A6FA-667A9498ED64Q41696601-23817013-963E-4670-8CD9-9894F74EE438
P2860
Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@ast
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@en
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@nl
type
label
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@ast
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@en
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@nl
altLabel
Recombinant measles virus vacc ...... t lethal Nipah virus challenge
@en
prefLabel
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@ast
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@en
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@nl
P2093
P2860
P1433
P1476
Recombinant measles virus vacc ...... lethal Nipah virus challenge.
@en
P2093
Chieko Kai
Frederic Jacquot
Fusako Ikeda
Hervé Raoul
Hiroki Sato
Miho Ishii
Misako Yoneda
Noriyo Nagata
P2860
P304
P356
10.1371/JOURNAL.PONE.0058414
P407
P577
2013-03-14T00:00:00Z